Acumen Pharmaceuticals, Inc. (ABOS)Healthcare | Biotechnology | Newton, United States | NasdaqGS
2.64 USD
+0.01
(0.380%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.65 +0.01 (0.379%) ⇧ (July 13, 2026, 5:18 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:29 a.m. EDT
The investment case for Acumen Pharmaceuticals is severely compromised by a catastrophic multi-year decline. Over the last four years, the stock has lost 92.43% of its value, driven by three consecutive years of negative annual performance. While the company holds a fortress-like balance sheet with a current ratio of 4.55 and manageable debt relative to cash, these strengths are irrelevant in a biotech sector where capital preservation is paramount without proven product revenue. The business is burning cash, with free cash flow of -$67 million and negative returns on equity, signaling that the current asset base is eroding value rather than generating it. The options market confirms this pessimism, with traders buying deep protection at strikes far above the current price while ignoring upside potential. Although the forward P/E is technically negative due to losses, this is not a value opportunity; it is a reflection of a company that has failed to execute its growth thesis over a sustained period. The recent price action shows some volatility, but the structural damage to shareholder value is too severe to recommend a long-term entry. |
| Model | MAE |
|---|---|
| MSTL_126 ✓ | 0.060143 |
| AutoTheta | 0.077404 |
| AutoETS | 0.092141 |
| AutoARIMA | 0.092146 |
| MSTL | 0.094123 |
| MSTL_74_126 | 0.102662 |
| MSTL_74 | 0.155783 |
Forecast horizon: 60 days | Selected: MSTL_126
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 1.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.377 |
| Excess Kurtosis | -0.85 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 35.622 |
| Market Cap | 190,680,832 |
| Forward P/E | -1.75 |
| Beta | 0.34 |
| Website | https://acumenpharm.com |
As of July 11, 2026, 4:29 a.m. EDT: Speculators are positioning aggressively for downside protection, evidenced by heavy put volume and open interest at the $5.00 strike compared to negligible call activity. Implied volatility is significantly elevated for out-of-the-money puts (12.88%) versus calls (3.28%), indicating a market expectation of a sharp drop rather than a rally. The lack of call open interest above the current price suggests a 'bear put spread' or hedging strategy is dominant.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7651007 |
| Address1 | 1,210-1220 Washington St. |
| Address2 | Suite 210 |
| All Time High | 26.98 |
| All Time Low | 0.855 |
| Ask | 3.31 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 924,560 |
| Average Daily Volume3 Month | 443,009 |
| Average Volume | 443,009 |
| Average Volume10Days | 924,560 |
| Beta | 0.341 |
| Bid | 1.95 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 1.211 |
| City | Newton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.64 |
| Current Ratio | 4.553 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.72 |
| Day Low | 2.57 |
| Debt To Equity | 35.622 |
| Display Name | Acumen Pharmaceuticals |
| Earnings Call Timestamp End | 1,778,587,200 |
| Earnings Call Timestamp Start | 1,778,587,200 |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,451,400 |
| Earnings Timestamp Start | 1,786,451,400 |
| Ebitda | -114,556,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.816 |
| Enterprise Value | 93,443,808 |
| Eps Current Year | -1.58455 |
| Eps Forward | -1.50668 |
| Eps Trailing Twelve Months | -1.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.4314 |
| Fifty Day Average Change | 0.20860004 |
| Fifty Day Average Change Percent | 0.08579421 |
| Fifty Two Week Change Percent | 76.51007 |
| Fifty Two Week High | 3.6 |
| Fifty Two Week High Change | -0.9599998 |
| Fifty Two Week High Change Percent | -0.26666662 |
| Fifty Two Week Low | 1.19 |
| Fifty Two Week Low Change | 1.45 |
| Fifty Two Week Low Change Percent | 1.2184874 |
| Fifty Two Week Range | 1.19 - 3.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,146,200,000 |
| Float Shares | 36,955,964 |
| Forward Eps | -1.50668 |
| Forward P E | -1.7521969 |
| Free Cashflow | -67,432,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 60 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -104,933,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06801 |
| Held Percent Institutions | 0.64157 |
| Implied Shares Outstanding | 72,227,580 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-01 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts. |
| Long Name | Acumen Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 190,680,832 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_8539521 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -113,276,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 189,958,535 |
| Number Of Analyst Opinions | 5 |
| Open | 2.59 |
| Operating Cashflow | -105,545,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 344 4190 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.3787875 |
| Post Market Price | 2.65 |
| Post Market Time | 1,783,977,516 |
| Previous Close | 2.63 |
| Price Eps Current Year | -1.6660882 |
| Price Hint | 4 |
| Price To Book | 2.1800168 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.43 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.380228 |
| Regular Market Day High | 2.72 |
| Regular Market Day Low | 2.57 |
| Regular Market Day Range | 2.57 - 2.72 |
| Regular Market Open | 2.59 |
| Regular Market Previous Close | 2.63 |
| Regular Market Price | 2.64 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 406,254 |
| Return On Assets | -0.42372 |
| Return On Equity | -0.93232 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 72,227,580 |
| Shares Percent Shares Out | 0.038599998 |
| Shares Short | 2,788,975 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,892,556 |
| Short Name | Acumen Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0554 |
| Short Ratio | 4.07 |
| Source Interval | 15 |
| State | MA |
| Symbol | ABOS |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.4 |
| Target Median Price | 8.0 |
| Total Cash | 128,398,000 |
| Total Cash Per Share | 1.778 |
| Total Debt | 31,161,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.315225 |
| Two Hundred Day Average Change | 0.32477522 |
| Two Hundred Day Average Change Percent | 0.14027804 |
| Type Disp | Equity |
| Volume | 406,254 |
| Website | https://acumenpharm.com |
| Zip | 2,465 |